Teva and Heptares enter $400m agreement for small-molecule migraine treatment
pharmafile | November 25, 2015 | News story | Research and Development | Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to develop, manufacture and commercialise new migraine treatments.
Israeli-based Teva and Heptares, which is a wholly owned subsidiary of Sosei Group Corporation, struck the deal for novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.
Under the terms of the agreement, Heptares will receive an upfront payment of $10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.
Michael Hayden, president of global R&D and chief scientific officer at Teva says: “We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine.”
“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.”
Malcolm Weir, chief executive officer of Heptares says: “This agreement is an exciting development for our CGRP antagonist program. Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”
Yasmita Kumar
Related Content
FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …
Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
